Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme An Academic Prospective Single-arm Phase II Clinical Trial Including Ranslational Research Studies

NCT00535379 is registered in ClinicalTrials.gov with Medical University Innsbruck as lead sponsor.

NCT NCT00535379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00535379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme An Academic Prospective Single-arm Phase II Clinical Trial Including Ranslational Research Studies
Lead sponsor
Medical University Innsbruck
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2007
Completion date
January 31, 2011
Enrollment
70 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme